NCT06686472View on ClinicalTrials.gov

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 3, 2024

Primary Completion Date

December 10, 2024

Study Completion Date

December 10, 2024

Conditions
Allergic Conjunctivitis
Interventions
DRUG

TL-925

TL-925 is an eye drop.

DRUG

Placebo

The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Trial Locations (1)

38119

RECRUITING

Telios Investigative Site, Memphis

All Listed Sponsors
lead

Telios Pharma, Inc.

INDUSTRY